Hepatitis B vaccination in mentally retarded: Effectiveness after 11 years

Vaccine

Volumn 17, Issue 6, 1999, Pages 602-606

  Vellinga, A ^a   Van Damme, P ^a   Weyler, J J ^a   Vranckx, R ^b   Meheus, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

ADULT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MENTAL RETARDATION; TIME FACTORS; VACCINATION;

EID: 0033547971     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00240-0     Document Type: Article

References (15)

1. Devuyst O., Maessen-Collard Y. Hepatitis B in a Belgian institution for mentally retarded patients: An epidemiological study. Acta Gastro-Enterol. Belg. 54:1991;12-18.
2. Krugman S., Giles J.P., Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological and immunological types of infection. JAMA. 200:1967;365-373.
3. Van Damme P., Kane M., Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. BMJ. 314:1997;1033-1036.
4. West D.J., Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen, implications for policy on booster vaccination. Vaccine. 14:1996;1019-1027.
5. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., Ostrow D.G., O'Malley P.M., Penley K.A. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315:1986;209-214.
6. Coursaget P., Leboulleux D., Soumare M., le Cann P., Yvonnet B., Chiron J.P., Coll-Seck A.M. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepatol. 21:1994;250-254.
7. Da Villa G., Peluso F., Picciotto L., Bencivenga M., Elia S., Pelliccia M.G. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life, follow-up at 5 and 10 years. Vaccine. 14:1996;1503-1505.
8. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J. Infect. Dis. 175:1997;674-677.
9. Tabor E., Cairns J., Gerety R.J., Bayley A.C. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J. Med. Virol. 40:1993;204-209.
10. Van Damme P., Vranckx R., Safary A., André F.E., Meheus A. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am. J. Med. 87:1989;26S-29S.
11. Hollinger F.B., Adam E., Heiberg D., Melnick J.L. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE, editors. Viral hepatitis. Philadelphia: The Franklin Institute Press, 1982:451-466.
12. Van Damme P., Vranckx R., Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome. Vaccine. 8:1990;S53-S55.
13. Avanzini M.A., Monafo V., De Amici M., Maccario R., Burgio G.R. Humoral immunodeficiencies in Down syndrome: Serum IgG subclass and antibody response to hepatitis B vaccine. Am. J. Med. Gen. (Suppl.). 70:1990;709-711.
14. Hayashi J., Noguchi A., Nakishima K., Morofuji M., Kashiwagi S. Long term observation of intradermal hepatitis B vaccination on mentally retarded patients. Eur. J. Epidemiol. 7:1991;649-653.
15. Van Damme P. Hepatitis B, epidemiology and evaluation of vaccination, Ph.D. Thesis. Antwerp: University of Antwerp Press, 1994.